Jamp-Rabeprazol 10mg & 20mg: Affected lot contains overweight or underweight Delayed-Release tablets.
Brand(s)
Last updated
Summary
Product
Jamp-Rabeprazole
Issue
Health products - Product safety
What to do
Consult your health care professional if you have any health concerns.
Affected products
Brand |
Product Name |
Market Authorization |
Dosage Form |
Strength |
Lot |
|---|---|---|---|---|---|
JAMP |
Jamp-Rabeprazol 10mg |
DIN 02415283 |
Tablet (delayed release) |
Rabeprazole Sodium 10mg |
EG24RJA002 |
JAMP |
Jamp-Rabeprazole 20mg |
DIN 02415291 |
Tablet (delayed release) |
Rabeprazole Sodium 20mg |
EG23RJC003, EG23RJC006, EG23RJC007, EG23RJC009, EG23RJC010, EG23RJD001, EG23RJD002, EG23RJD003, EG23RJD004, EG24RJD001 |
Issue
Affected lot contains overweight or underweight Delayed-Release tablets.
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Wholesalers, Retailers, Healthcare Establishments
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
JAMP Pharma Corporation.
1310 Nobel,
Boucherville, QC,
J4B 5H3
Published by
Health Canada
Audience
General public
Healthcare
Industry
Recall class
Type II
Identification number
RA-75949
Get notified
Receive notifications for new and updated recalls and alerts by category.